HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy

Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, and Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
AIDS (London, England) (Impact Factor: 5.55). 09/2008; 22(13):1583-8. DOI: 10.1097/QAD.0b013e328305bd77
Source: PubMed


An important pending question is whether temporary highly active antiretroviral therapy during primary HIV infection can influence viral rebound dynamics and the subsequently established viral setpoint, through preservation and enhancement of HIV-1-specific immune responses, or through other mechanisms.
We included all patients from two prospective studies who underwent a single treatment interruption while being well suppressed on highly active antiretroviral therapy. One group started highly active antiretroviral therapy during primary HIV infection, and the other group started it during chronic HIV infection with CD4 cell counts above 350 cells/microl. Data were collected up to 48 weeks from treatment interruption. The median time to viral rebound was analysed for three levels of viraemia: 50, 500 and 5000 copies HIV-RNA/ml plasma.
The median time to viral rebound was significantly longer in primary HIV infection patients (n = 24) than in chronic HIV infection patients (n = 46): 8 versus 4 weeks (P < 0.001 for all three endpoints). In two primary HIV infection patients, no rebound of plasma HIV-1 RNA over 50 copies/ml occurred. In the first 4 weeks after treatment interruption, CD4+ T-cell counts declined with a median of -5.0 cells/microl blood per week in the primary HIV infection group and -45 cells/microl blood per week in the chronic HIV infection group (P < 0.05). From week 4 to 48, the decline in CD4+ T-cell count was similar in both groups.
Plasma viral load and CD4 dynamics after a single interruption of highly active antiretroviral therapy were different for primary HIV infection and chronic HIV infection patients. Viral rebound is delayed or absent and early CD4 cell count decline after treatment interruption is less pronounced in primary HIV infection patients.

Download full-text


Available from: Hanneke Schuitemaker
  • Source
    • "Reservoirs levels in post-treatment controllers during the control phase were very low and it was mostly associated to the transitional memory CD4 þ T cell subset, due to a skewed distribution of quiescent CD4 þ T cell subsets in these patients (Saez-Cirion et al., 2013) (Fig. 2). Treatment interruption in patients who started cART during chronic phase leads to viral rebound within weeks, with viral loads frequently reaching pretreatment set-point levels (Fernandez Guerrero et al., 2005; Steingrover et al., 2008; Wit et al., 2005). Notwithstanding, some patients that started cART during chronic phase were also described to maintain controlled levels of viremia after therapy discontinuation (Van Gulck et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thirty years after the identification of HIV, a cure for HIV infection is still to be achieved. Advances of combined antiretroviral therapy (cART) in recent years have transformed HIV infection into a chronic disease when treatment is available. However, in spite of the favorable outcomes provided by the newer therapies, cART is not curative and patients are at risk of developing HIV-associated disorders. Moreover, universal access to antiretroviral treatment is restricted by financial obstacles. This review discusses the most recent strategies that have been developed in the search for an HIV cure and to improve life quality of people living with HIV.
    Full-text · Article · Apr 2014 · Virology
  • Source
    • "Thus, thwarting HIV replication by introducing HAART in the early phases of infection could have a substantial impact on the whole disease course. In particular, suggested factors that may contribute to the observed better viral control after treatment interruption in very early treated patients are [3]: i) early arrest of viral escape, leaving the virus vulnerable; ii) preservation or even enhancement of the immune response resulting from the early clearing of antigen; iii) prevention of the establishment of a pool of HIV-specific memory CD4 T cells thus leaving fewer target cells available for viral infection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: When to initiate antiretroviral therapy in HIV infected patients is a difficult clinical decision. Actually, it is still a matter of discussion whether early highly active antiretroviral therapy (HAART) during primary HIV infection may influence the dynamics of the viral rebound, in case of therapy interruption, and overall the main disease course. In this article we use a computational model and clinical data to identify the role of HAART timing on the residual capability to control HIV rebound after treatment suspension. Analyses of clinical data from three groups of patients initiating HAART respectively before seroconversion (very early), during the acute phase (early) and in the chronic phase (late), evidence differences arising from the very early events of the viral infection. The computational model allows a fine grain assessment of the impact of HAART timing on the disease outcome, from acute to chronic HIV-1 infection. Both patients' data and computer simulations reveal that HAART timing may indeed affect the HIV control capability after treatment discontinuation. In particular, we find a median time to viral rebound that is significantly longer in very early than in late patients. A timing threshold is identified, corresponding to approximately three weeks post-infection, after which the capability to control HIV replication is lost. Conversely, HAART initiation occurring within three weeks from the infection could allow to preserve a significant control capability. This time could be related to the global triggering of uncontrolled immune activation, affecting residual immune competence preservation and HIV reservoir establishment.
    Full-text · Article · Mar 2011 · BMC Infectious Diseases
  • Source
    • "However, there are two major differences between the cohorts used in [6] and in the present article: a) in the former, patients have been recruited with a negative western blot for anti-HIV antibodies hence before seroconversion while in the latter, cohort data includes patients classified in stage IV, V and VI with respect to [9] (see Table 2); b) in [6] patients were treated with an intensive HAART consisting of two or three NRTIs plus a NNRTI and a PI, whereas our patients were treated with just two NRTI and one PI. These two features might be the cause of a lower level of viremia at the end of HAART accounting for a slower viral rebound in [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The optimal stage for initiating antiretroviral therapies in HIV-1 bearing patients is still a matter of debate. We present computer simulations of HIV-1 infection aimed at identifying the pro et contra of immediate as compared to deferred Highly Active Antiretroviral Therapy (HAART). Our simulations highlight that a prompt specific CD8+ cytotoxic T lymphocytes response is detected when therapy is delayed. Compared to very early initiation of HAART, in deferred treated patients CD8+ T cells manage to mediate the decline of viremia in a shorter time and, at interruption of therapy, the virus experiences a stronger immune pressure. We also observe, however, that the immunological effects of the therapy fade with time in both therapeutic regimens. Thus, within one year from discontinuation, viral burden recovers to the value at which it would level off in the absence of therapy.In summary, simulations show that immediate therapy does not prolong the disease-free period and does not confer a survival benefit when compared to treatment started during the chronic infection phase. Our conclusion is that, since there is no therapy to date that guarantees life-long protection, deferral of therapy should be preferred in order to minimize the risk of adverse effects, the occurrence of drug resistances and the costs of treatment.
    Full-text · Article · Oct 2009 · BMC Infectious Diseases
Show more